HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $843,227 | -10.3% | 22,074 | +0.6% | 0.01% | 0.0% |
| Q2 2023 | $939,654 | +13.3% | 21,944 | +1.0% | 0.01% | 0.0% |
| Q1 2023 | $829,372 | -32.2% | 21,717 | 0.0% | 0.01% | -87.1% |
| Q4 2022 | $1,223,362 | -25.9% | 21,717 | -48.0% | 0.06% | +226.3% |
| Q3 2022 | $1,652,000 | -10.1% | 41,782 | +0.0% | 0.02% | +18.8% |
| Q2 2022 | $1,838,000 | +10.3% | 41,765 | -0.0% | 0.02% | +23.1% |
| Q1 2022 | $1,666,000 | -0.9% | 41,772 | -0.1% | 0.01% | 0.0% |
| Q4 2021 | $1,681,000 | -50.4% | 41,810 | -49.8% | 0.01% | -40.9% |
| Q3 2021 | $3,386,000 | +78.8% | 83,234 | +99.6% | 0.02% | +29.4% |
| Q2 2021 | $1,894,000 | +9.0% | 41,700 | 0.0% | 0.02% | 0.0% |
| Q1 2021 | $1,738,000 | +618.2% | 41,700 | +167.8% | 0.02% | +325.0% |
| Q3 2019 | $242,000 | -9.7% | 15,570 | -0.1% | 0.00% | -20.0% |
| Q2 2019 | $268,000 | +9.4% | 15,587 | +2.5% | 0.01% | 0.0% |
| Q1 2019 | $245,000 | +8.4% | 15,210 | -1.6% | 0.01% | 0.0% |
| Q4 2018 | $226,000 | – | 15,465 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |